Biochip array technology from Randox allows multiple results from a single patient sample, minimising biological variation and resulting in a more rapid and accurate diagnosis
The FDA-cleared biochip array technology was designed by Randox Laboratories and was granted the prestigious MacRobert award for engineering in 2003.
Based on Elisa principles of competitive, sandwich and antibody capture assays biochip array technology utilises a 9mm2 biochip as a reaction platform, with multiple specific ligands (antibodies or antigens) attached at pre-defined sites on the surface.
Up to 23 separate tests can be spotted as discrete test regions on the surface of the biochip allowing 23 different results from as little as 7ml of patient sample.
Biochip tests are grouped together as arrays and allow the detection of cytokines and growth factors, fertility and thyroid hormones, cell adhesion molecules and drugs of abuse.
Arrays are also available for the detection of biomarkers associated with cardiovascular disease and cancer.
The Biochip platform is suitable for both proteomic and genomic analysis, providing test standardisation for better performance and accuracy.
Randox says it has a very strong R+D ethos with 200 R+D staff and currently have more tests in development than any other diagnostic company in the world.
